Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1
Authors
Lin, J. J.Drilon, A. E.
Cho, B. C.
Felip, E.
De Langen, A.
Yang, N.
Kim, S. W.
Lu, S.
Kao, S. C. H.
Velcheti, V.
Moro Sibilot, D. L.
Solomon, B. J.
Dziadziuszko, R.
Krebs, Matthew G
Cheema, P. K.
Dooms, C. A.
Stopatschinskaja, S.
Trone, D.
Ades, F.
Camidge, D. R.
Affiliation
Massachusetts General Hospital Cancer Center, Boston, MAIssue Date
2023
Metadata
Show full item recordCitation
Lin JJ, Drilon AE, Cho BC, Felip E, De Langen A, Yang N, et al. Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003685.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.9017Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9017Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.9017